Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Farm bill

This article was originally published in The Tan Sheet

Executive Summary

Heads to conference following Senate passage (58-40) Feb. 13. Amendment 2471, incorporated into S 1731 on the same day, includes provision allowing low-income families to use food stamp benefits to purchase dietary supplements such as multivitamins, folic acid, calcium. The amendment, proposed as a substitute for original bill by Sen. Tom Harkin (D-Iowa) in December, represents first time the vitamin language has made it through the Senate (1"The Tan Sheet" Dec. 17, 2001, p. 6). Conferees will meet within next few weeks; House version does not contain supplements provision...

You may also be interested in...



Food Stamp Vitamin/Mineral Supplement Study Urged In Senate Farm Bill

A report on the effects of allowing vitamin and mineral supplements to be purchased with food stamps would be required as part of an amendment to the farm bill introduced in the Senate Dec. 11

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel